Cernilton and CP/CPPS

Studies performed in patients with CP-CPPS using Cernilton
From Wagenlehner F et al., 2011; 26th Annual EAU Congress, Vienna
Study type Dosage (tablets) Duration Pat. Clinical response ° Author, year
Randomized,
double blind,
placebo contr
2 t.i.d. 12 (24) weeks
(IIIA)
70 (139) 69% pollen extract vs.
49% placebo (p=0.015)
°>25% improvement NIH-CPSI or
6 point decrease of NIH-CPSI
Wagenlehner et al., 2009
Download PDF »
Open,
non-comparative
1 t.i.d. 6 months
(IIIA/B)
90 63%
°global objective assessment
Rugendorff et al., 1993
Open,
non-comparative
2 b.i.d. 1 to 8 months
(IIIA/B)
15 87%
°global subjective assessment
Buck et al., 1989
Open,
non-comparative
3 t.i.d. 4 to 6 weeks
(IIIA/B)
24 63%
°>50% improvement NIH-CPSI
Monden et al., 2002
Open,
non-comparative
2 t.i.d. 12 weeks
(IIIA/B)
32 66%
°global objective assessment
Jodai et al. 1988
Open,
non-comparative
2 t.i.d. 8 weeks
(IIIA/B)
25 76%
°global objective assessment
Suzuki et al. 1992
Total 6 3 to 9/ d 4 to 32 weeks 256 63 to 87%

Cernilton is a registered trademark of AB Cernelle
AB CERNELLE • HÖGANÄSVÄGEN 365 • SE-262 94 ÄNGELHOLM • SWEDEN • TEL +46 (0)42 69 230 • This email address is being protected from spambots. You need JavaScript enabled to view it.WWW.CERNELLE.COMSITEMAP